Comparison · NCT03425539-sae
Lucerastat vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lucerastat vs Placebo: serious adverse events. Trial comparisons, record NCT03425539-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03425539-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0625 | 0.027 | 0.138 | wilson | |
| Risk in group 2 | 0.027 | 0.00479 | 0.138 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0355 | -0.0813 | 0.114 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.31 | 0.28 | 19.1 | log | |
| Odds ratio, group 1 over group 2 | 2.4 | 0.27 | 21.3 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Lucerastat than on Placebo | 28.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lucerastat | Lucerastat (ACT-434964) was provided as hard-gelatin capsules containing 250 mg of lucerastat.~Capsules were administered orally b.i.d. to provide a lucerastat dose of 250, 500, 750, or 1000 mg b.i.d. based on the subject's eGFR. | 5 | 80 | EG000 |
| Group 2 | Placebo | Matching placebo capsules were administered orally b.i.d., with the number of capsules administered based on the subject's eGFR. | 1 | 37 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Treatment-emergent adverse events from the 6-month treatment period are reported. Adverse events were considered treatment-emergent if the onset date was between the first intake of study treatment up to 30 days after the end of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
- NCT number
- NCT03425539
- Phases
- PHASE3
- Conditions
- Fabry Disease
- Interventions
- Lucerastat, Placebo
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Results first posted
- 2024-08-09
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03425539?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03425539-sae